Siren L.L.C. Has $3.50 Million Position in Vigil Neuroscience, Inc. $VIGL

Siren L.L.C. lessened its holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 1.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,967,064 shares of the company’s stock after selling 23,974 shares during the period. Siren L.L.C. owned 4.21% of Vigil Neuroscience worth $3,501,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Aberdeen Group plc boosted its position in Vigil Neuroscience by 226.3% during the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company’s stock worth $3,070,000 after purchasing an additional 1,196,048 shares during the period. 683 Capital Management LLC boosted its holdings in shares of Vigil Neuroscience by 14.8% during the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company’s stock worth $2,380,000 after buying an additional 180,420 shares during the period. Blair William & Co. IL boosted its holdings in shares of Vigil Neuroscience by 219.1% during the 1st quarter. Blair William & Co. IL now owns 1,033,577 shares of the company’s stock worth $1,840,000 after buying an additional 709,677 shares during the period. Ensign Peak Advisors Inc grew its stake in Vigil Neuroscience by 16.1% in the 4th quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company’s stock valued at $1,195,000 after buying an additional 97,580 shares during the last quarter. Finally, Woodline Partners LP raised its holdings in Vigil Neuroscience by 239.1% in the 4th quarter. Woodline Partners LP now owns 488,756 shares of the company’s stock valued at $831,000 after acquiring an additional 344,614 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Stock Performance

NASDAQ:VIGL opened at $8.05 on Friday. The company has a market cap of $383.90 million, a price-to-earnings ratio of -3.93 and a beta of 3.33. Vigil Neuroscience, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $8.10. The stock has a fifty day moving average price of $8.03 and a 200-day moving average price of $5.01.

Analysts Set New Price Targets

VIGL has been the subject of a number of research analyst reports. Wedbush cut Vigil Neuroscience from a “strong-buy” rating to a “hold” rating and reduced their price objective for the stock from $13.00 to $8.00 in a report on Thursday, May 22nd. Jefferies Financial Group downgraded Vigil Neuroscience to a “hold” rating in a research note on Thursday, May 22nd. HC Wainwright lowered Vigil Neuroscience from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $14.00 to $8.00 in a report on Tuesday, May 27th. William Blair cut Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 22nd. Finally, Citizens Jmp cut shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 22nd. Ten analysts have rated the stock with a Hold rating, According to MarketBeat, Vigil Neuroscience currently has a consensus rating of “Hold” and a consensus price target of $10.80.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.